Previous 10 | Next 10 |
Clover Biopharmaceuticals said that a third dose of its COVID-19 vaccine showed neutralizing antibody levels against Omicron variants in a trial. Clover noted that it created its COVID-19 vaccine candidate by combining SCB-2019 with Dynavax Technologies (NASDAQ:DVAX) CpG 1018 advanc...
SCB-2019 (CpG 1018/Alum) as a third dose exhibited a 19-fold boost in neutralizing antibodies against Omicron BA.2 variant among baseline seronegative participants New positive data adds to growing body of evidence supporting potential use of SCB-2019 (CpG 1018/Alum) as a univer...
Biotech Dynavax Technologies (NASDAQ: DVAX) had a terrific Thursday on the stock market. The company's shares rocketed nearly 7% higher on the day, trouncing the S&P 500 index's upward crawl of just under 1%. More good news from an important partner across the Atlantic was the c...
-- Study to evaluate SCB-2019 (CpG 1018/Alum) as a heterologous booster in individuals previously vaccinated with CoronaVac™ ( Sinovac Inactivated Vaccine ), Comirnaty ® ( Pfizer mRNA Vaccine ), and Vaxzevria ® ( AstraZene...
The ADRs of Valneva SE (NASDAQ:VALN) dropped for the third straight session on Monday after the French vaccine maker said that its deal with European Commission for an experimental COVID-19 shot hangs in the balance. The whole virus, inactivated vaccine candidate, named VLA2001, is designed t...
-- Changxing manufacturing facility readiness and CMC activities impacted by COVID-19 outbreak in China - the facility is now expected to be ready for GMP inspections in Q3-2022 -- -- Regulatory submissions to the China NMPA, EMA, and the WHO for SCB-2019 (CpG 1018/Al...
Dynavax to Present at the William Blair 42nd Annual Growth Stock Conference PR Newswire EMERYVILLE, Calif. , May 25, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and comm...
DVAX will do well as long as the coronavirus vaccine demand exists. While the urgency is somewhat abated, an evolving endemic situation may continue to need CpG 1018. If it doesn't, HEPLISAV-B alone will not save the day. For further details see: Dynavax: Evolving Endemi...
Several days after experiencing a pleasant share price pop on good regulatory news, Dynavax (NASDAQ: DVAX) repeated the feat on Thursday. An important partner for the company reported an encouraging development that morning, also in the regulatory sphere. Investors lapped up the fre...
Although optimists currently believe we're getting past the worst of the coronavirus pandemic, Dynavax Technologies (NASDAQ: DVAX) shares saw a lift Monday on positive vaccine news. A popular coronavirus stock in the worst days of the outbreak, an important business partner of the c...
News, Short Squeeze, Breakout and More Instantly...
Dynavax Technologies Corporation Company Name:
DVAX Stock Symbol:
NASDAQ Market:
Dynavax Technologies Corporation Website:
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 PR Newswire EMERYVILLE, Calif. , July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company dev...
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program PR Newswire EMERYVILLE, Calif. , June 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing inn...
2024-06-21 02:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...